Prognostic and clinicopathological value of C-reactive protein in patients with bladder cancer: a meta-analysis

Background The prognostic value of C-reactive protein (CRP) in patients with bladder cancer (BCa) has been widely analysed; however, the results remain conflicting. Therefore, we performed this meta-analysis to identify the precise role of CRP level in predicting BCa prognosis.Methods PubMed, Web of...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiangping Feng, Zongxin Zhang, Shuiying Mao
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Annals of Medicine
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/07853890.2024.2445781
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850088646825213952
author Xiangping Feng
Zongxin Zhang
Shuiying Mao
author_facet Xiangping Feng
Zongxin Zhang
Shuiying Mao
author_sort Xiangping Feng
collection DOAJ
description Background The prognostic value of C-reactive protein (CRP) in patients with bladder cancer (BCa) has been widely analysed; however, the results remain conflicting. Therefore, we performed this meta-analysis to identify the precise role of CRP level in predicting BCa prognosis.Methods PubMed, Web of Science, Embase and Cochrane Library databases were comprehensively searched until 19 April 2024. The impact of CRP level on predicting the prognosis of patients with BCa was examined using combined hazard ratios (HRs) and 95% confidence intervals (CIs). The relationship between CRP level and BCa clinicopathological characteristics was investigated by combining the odds ratios (ORs) with 95%CIs.Results Twenty studies with 7276 patients were enrolled in this study. As revealed by pooled data, elevated CRP levels were markedly related to poor overall survival (OS) (HR = 2.02, 95%CI = 1.41–2.90, p < .001), inferior cancer-specific survival (CSS) (HR = 1.46, 95%CI = 1.29–1.66, p < .001), shortened recurrence-free survival (RFS) (HR = 1.25, 95%CI = 1.17–1.33, p < .001) and dismal progression-free survival (PFS) (HR = 2.28, 95%CI = 1.80–2.90, p < .001) in BCa patients. Nevertheless, there was no significant relationship between CRP level and sex, tumour size, tumour grade or lymph node metastasis (LNM) in BCa.Conclusions Elevated CRP levels were significantly related to poor OS, CSS, RFS and PFS of BCa patients with BCa. CRP could act as a reliable biomarker for predicting the short- and long-term survival of patients with BCa in clinical practice.
format Article
id doaj-art-0f4cba7e893c401aa4d949069b0ed4d3
institution DOAJ
issn 0785-3890
1365-2060
language English
publishDate 2025-12-01
publisher Taylor & Francis Group
record_format Article
series Annals of Medicine
spelling doaj-art-0f4cba7e893c401aa4d949069b0ed4d32025-08-20T02:42:59ZengTaylor & Francis GroupAnnals of Medicine0785-38901365-20602025-12-0157110.1080/07853890.2024.2445781Prognostic and clinicopathological value of C-reactive protein in patients with bladder cancer: a meta-analysisXiangping Feng0Zongxin Zhang1Shuiying Mao2Clinical Laboratory, Huzhou Maternity &amp; Child Health Care Hospital, Huzhou, ChinaClinical Laboratory, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, ChinaClinical Laboratory, Huzhou Maternity &amp; Child Health Care Hospital, Huzhou, ChinaBackground The prognostic value of C-reactive protein (CRP) in patients with bladder cancer (BCa) has been widely analysed; however, the results remain conflicting. Therefore, we performed this meta-analysis to identify the precise role of CRP level in predicting BCa prognosis.Methods PubMed, Web of Science, Embase and Cochrane Library databases were comprehensively searched until 19 April 2024. The impact of CRP level on predicting the prognosis of patients with BCa was examined using combined hazard ratios (HRs) and 95% confidence intervals (CIs). The relationship between CRP level and BCa clinicopathological characteristics was investigated by combining the odds ratios (ORs) with 95%CIs.Results Twenty studies with 7276 patients were enrolled in this study. As revealed by pooled data, elevated CRP levels were markedly related to poor overall survival (OS) (HR = 2.02, 95%CI = 1.41–2.90, p < .001), inferior cancer-specific survival (CSS) (HR = 1.46, 95%CI = 1.29–1.66, p < .001), shortened recurrence-free survival (RFS) (HR = 1.25, 95%CI = 1.17–1.33, p < .001) and dismal progression-free survival (PFS) (HR = 2.28, 95%CI = 1.80–2.90, p < .001) in BCa patients. Nevertheless, there was no significant relationship between CRP level and sex, tumour size, tumour grade or lymph node metastasis (LNM) in BCa.Conclusions Elevated CRP levels were significantly related to poor OS, CSS, RFS and PFS of BCa patients with BCa. CRP could act as a reliable biomarker for predicting the short- and long-term survival of patients with BCa in clinical practice.https://www.tandfonline.com/doi/10.1080/07853890.2024.2445781C-reactive proteinbladder cancermeta-analysisprognosisbiomarker
spellingShingle Xiangping Feng
Zongxin Zhang
Shuiying Mao
Prognostic and clinicopathological value of C-reactive protein in patients with bladder cancer: a meta-analysis
Annals of Medicine
C-reactive protein
bladder cancer
meta-analysis
prognosis
biomarker
title Prognostic and clinicopathological value of C-reactive protein in patients with bladder cancer: a meta-analysis
title_full Prognostic and clinicopathological value of C-reactive protein in patients with bladder cancer: a meta-analysis
title_fullStr Prognostic and clinicopathological value of C-reactive protein in patients with bladder cancer: a meta-analysis
title_full_unstemmed Prognostic and clinicopathological value of C-reactive protein in patients with bladder cancer: a meta-analysis
title_short Prognostic and clinicopathological value of C-reactive protein in patients with bladder cancer: a meta-analysis
title_sort prognostic and clinicopathological value of c reactive protein in patients with bladder cancer a meta analysis
topic C-reactive protein
bladder cancer
meta-analysis
prognosis
biomarker
url https://www.tandfonline.com/doi/10.1080/07853890.2024.2445781
work_keys_str_mv AT xiangpingfeng prognosticandclinicopathologicalvalueofcreactiveproteininpatientswithbladdercancerametaanalysis
AT zongxinzhang prognosticandclinicopathologicalvalueofcreactiveproteininpatientswithbladdercancerametaanalysis
AT shuiyingmao prognosticandclinicopathologicalvalueofcreactiveproteininpatientswithbladdercancerametaanalysis